Table 2.
Summary of included RCTs
| PARP Inhibitors | Number of Phase II Studies | Number of Phase III Studies | Sample Size (PARP group/control group) | Interventions | Median treatment duration (PARP group) | Cancer | |
|---|---|---|---|---|---|---|---|
| Treatment regime (PARP group versus control group) | Number of studies | ||||||
| Niraparib | 0 | 4 | 1153/571 | A | 4 | 44 days, 369 days | Ovarian cancer, Lung Cancer |
| Olaparib | 8 | 6 | 2418/1726 | A | 5 | 8 weeks ~ 24.6 months | Ovarian cancer, lung cancer, pancreatic cancer, prostate cancer, breast cancer, and gastric cancer |
| B | 3 | ||||||
| C | 6 | ||||||
| Veliparib | 7 | 3 | 1953/1275 | C | 10 | 8 weeks ~ 36 weeks | Ovarian cancer, breast cancer, prostate cancer, lung cancer, colorectal cancer, pancreatic cancer, pancreas adenocarcinoma |
| Rucaparib | 0 | 3 | 1029/412 | A | 2 | 7.3 months ~ 14.7 months | Ovarian cancer, peritoneal cancer |
| B | 1 | ||||||
| Iniparib | 1 | 0 | 78/39 | C | 1 | 15 weeks | Lung cancer |
| Totle | 16 | 16 | 6631/4023 | A,B,C | 32 | 44 days ~ 14.7 months | Ovarian cancer, lung cancer, pancreatic cancer, prostate cancer, breast cancer, peritoneal cancer, colorectal cancer, gastric cancer, pancreas adenocarcinoma |
PARP poly(adenosine diphosphate-ribose) polymerase, A: PARP inhibitors versus placebo, B: PARP inhibitors versus other anticancer drugs, C: PARP inhibitors + other anticancer drugs versus other anticancer drugs